| Literature DB >> 28930267 |
Mahesh Chandra1, Om Prakash2, Ravendra Kumar3, Rakesh Kumar Bachheti4, Brij Bhushan5, Mahesh Kumar6, Anil Kumar Pant7.
Abstract
Background:Callicarpa macrophylla (Varbenaceae) is a medicinal shrub and is traditionally used in India, China, and South Asia.Entities:
Keywords: Callicarpa macropylla; caryophillene oxide; pharmacology; phylocladene; β-selinene
Year: 2017 PMID: 28930267 PMCID: PMC5622387 DOI: 10.3390/medicines4030052
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Essential oil composition from different parts of Callicarpa macropylla.
| S.N. | Compounds Name | KI/RI | FID % | ||
|---|---|---|---|---|---|
| CMLEO | CMOE-I | CMEO-II | |||
| 1 | hex-2 | 850 | 0.20 | - | - |
| 2 | α-pinene | 933 | 0.06 | - | 0.40 |
| 3 | β-pinene | 943 | 0.53 | 1.07 | 2.32 |
| 4 | 1-octene-3one | 943 | 0.02 | 0.12 | 0.02 |
| 5 | 3-octanone | 952 | 0.10 | 0.12 | 0.06 |
| 6 | banzaldehide | 960 | 0.14 | - | - |
| 7 | sabinene | 972 | 0.17 | 0.40 | 0.25 |
| 8 | hexanoic acid | 979 | - | 0.47 | - |
| 9 | myrcene | 991 | - | - | 0.04 |
| 10 | hex-3 | 1008 | 0.01 | - | - |
| 11 | p-cymene | 1025 | 0.13 | 0.41 | 0.14 |
| 12 | limonene | 1030 | - | 0.15 | 0.12 |
| 13 | 1,8-cineole | 1032 | 2.23 | 3.10 | 1.62 |
| 14 | β-ocimene | 1046 | - | - | 0.31 |
| 15 | 2-nonanone | 1052 | 0.02 | - | - |
| 16 | 1067 | - | 0.27 | - | |
| 17 | 1069 | - | 0.21 | - | |
| 18 | 1086 | - | 0.15 | - | |
| 19 | linalool | 1101 | 0.20 | 0.86 | - |
| 20 | nopinone | 1139 | - | 0.50 | - |
| 21 | sabina ketone | 1154 | 0.03 | - | - |
| 22 | pinocarvone | 1164 | - | 0.64 | 0.45 |
| 23 | terpinen-4-ol | 1180 | - | 0.43 | - |
| 24 | myrtenal | 1197 | 0.23 | 0.74 | 0.20 |
| 25 | 1-butyryl-1,2,3,6-tetrahydropyridine | 1249 | 0.05 | ||
| 26 | 3,9-dodecadiyn | 1249 | 0.37 | - | - |
| 27 | bornyl acetate | 1285 | - | 0.42 | - |
| 28 | leden oxide (I) | 1293 | - | 0.40 | - |
| 29 | myrtenal acetate | 1326 | - | 0.19 | - |
| 30 | α-copaene | 1375 | 0.35 | - | 0.27 |
| 31 | β-elemene | 1390 | 0.98 | 0.82 | 0.61 |
| 32 | β-cubebene | 1392 | 0.10 | 0.09 | 0.48 |
| 33 | α-gurjunene | 1406 | 0.50 | 0.95 | 0.15 |
| 34 | nopyl acetate | 1413 | - | 0.26 | - |
| 35 | β-caryophelline | 1424 | 3.26 | - | 1.84 |
| 36 | ( | 1424 | 0.44 | - | 0.11 |
| 37 | aromadandrene | 1438 | - | 2.14 | 0.19 |
| 38 | 4-camphenylbutan-2-one | 1451 | - | 0.80 | - |
| 39 | α-humulene | 1454 | - | - | 0.14 |
| 40 | aromadendrene oxide II | 1462 | 0.43 | 0.46 | 0.25 |
| 41 | 9 | 1464 | 6.23 | 1.27 | 3.43 |
| 42 | α-selinene | 1474 | 0.26 | ||
| 43 | α-cubebene | 1480 | 0.11 | - | - |
| 44 | ar-curcumene | 1480 | 0.19 | 0.10 | 0.14 |
| 45 | β-selinene | 1492 | 37.51 | 44.66 | 57.01 |
| 46 | amorphene | 1502 | 0.41 | - | - |
| 47 | perhydropyrene | 1502 | 0.37 | ||
| 48 | caryophelline oxide | 1507 | 7.34 | 8.74 | 5.0 |
| 49 | δ-cadinine | 1518 | 0.85 | 0.41 | 0.59 |
| 50 | 1527 | 0.35 | 0.15 | 0.31 | |
| 51 | globulol | 1530 | 0.42 | - | - |
| 52 | Z-α-bisaboline epoxide | 1531 | 0.21 | ||
| 53 | α-agarofuron | 1548 | - | 0.40 | - |
| 54 | ( | 1561 | - | 0.20 | - |
| 55 | longicamphenylone | 1563 | - | 3.08 | - |
| 56 | longipinocarvone | 1569 | 4.96 | 1.17 | 2.0 |
| 57 | sphathulenol | 1576 | 1.06 | 2.10 | 0.30 |
| 58 | β-copaen-4 α-ol | 1590 | 1.03 | - | - |
| 59 | 1590 | 0.63 | 0.71 | - | |
| 60 | fokienol | 1596 | 0.38 | 0.31 | - |
| 61 | salvial-4 (14)-en-1-one | 1596 | 0.73 | - | - |
| 62 | β-oplopanone | 1607 | 0.33 | ||
| 63 | humulene epoxide II | 1613 | 0.21 | - | - |
| 64 | 1637 | - | 0.31 | - | |
| 65 | solavetivone | 1645 | 0.99 | 0.30 | 0.40 |
| 66 | cedren-13-ol | 1646 | - | 0.52 | - |
| 67 | vulgarone | 1649 | 2.92 | 1.02 | 0.40 |
| 68 | α-muurolol | 1651 | 1.76 | - | - |
| 69 | cadalene | 1677 | - | 0.32 | - |
| 70 | khusinol | 1679 | - | - | 0.10 |
| 71 | juniper camphor | 1696 | 3.13 | 3.03 | - |
| 72 | 1760 | 0.12 | - | - | |
| 73 | 14-oxy α-muurolene | 1767 | 2.50 | - | - |
| 74 | phyllocladene | 1789 | 9.76 | 5.80 | 12.38 |
| 75 | cupressene | 1880 | - | 0.47 | - |
| 76 | 5-octen-2-one | 1932 | 0.53 | ||
| 77 | androsta-4,16-dien-3-one | 1933 | 0.71 | 0.50 | 0.70 |
| 78 | androsta-3,5-dien-7-one | 1933 | 0.55 | 0.26 | 0.32 |
| 79 | 6-androstanone | 1940 | 0.13 | ||
| 80 | n-hexadecanoic acid | 1977 | 0.43 | ||
| 81 | 9Z,12Z,15Z-octadecatrien-1-ol | 2077 | 0.20 | ||
| 82 | pimara-7,15-dien-3-one | 2097 | 0.36 | 0.16 | 0.24 |
| 83 | thunbergol | 2211 | - | 0.98 | 0.23 |
| 84 | andrographolide | 2944 | 0.84 | 0.74 | |
S.N. = Serial number.:, KI/RI= Kovat indicest/retention indices.
Figure 1Reducing power activity.
Figure 2Chelating activity.
Figure 3DPPH radical scavenging activity.
Figure 4Super oxide scavenging activity.
Figure 5Nitric oxide radical scavenging activity.
Figure 6Hydroxyl radical scavenging activity.
Antioxidant properties in terms of IC50 values in essential oils from different areal parts of C. macrophylla.
| Extracts | (IC 50 in (µL/µg)/mL)/R2 | % Absorbance (Reducing Power) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Radical scavenging Activities | Chelating Activity | At lower Dose Level (5 µL/µg)/mL | At Higher Dose Level (25 µL/µg)/mL | |||||||||
| DPPH Scavenging | NO scavenging | Super Oxide Scavenging | OH Scavenging | |||||||||
| IC50 | IC50 | IC50 | IC50 | IC50 | ||||||||
| 18.35 ± 0.18 | 0.933 ± 0.003 | 10.61 ± 0.02 | 0.941 ± 0.000 | 18.58 ± 0.19 | 0.956 ± 0.006 | 16.06 ± 0.16 | 0.963 ± 0.006 | 14.38 ± 0.27 | 0.913 ± 0.009 | 0.426 ± 0.004 | 0.602 ± 0.000 | |
| 20.29 ± .11 | 0.960 ± 0.06 | 11.18 ± 0.06 | 0.95 ± 0.004 | 20.79 ± 0.30 | 0.954 ± 0.005 | 18.59 ± 0.25 | 0.960 ± 0.006 | 13.42 ± 0.17 | 0.950 ± 0.004 | 0.411 ± 0.003 | 0.573 ± 0.000 | |
| 15.66 ± 0.03 | 0.961 ± 00.005 | 0.922 ± 0.002 | 17.49 ± 0.13 | 0.954 ± 0.015 | 14. 59 ± 0.18 | 0.956 ± 0.016 | 11.49 ± 0.87 | 0.979 ± 0.006 | 0.450 ± 0.004 | 0.418 ± 0.000 | ||
| 8.55 ± 0.10 | 0.947 ± 0.005 | NA | NA | NA | NA | NA | NA | NA | NA | 0.55 ± 0.008 | 0.735 ± 0.009 | |
| 8.18 ± 0.11 | 0.950 ± 0.004 | NA | NA | NA | NA | NA | NA | NA | NA | 0.455 ± 0.006 | 0.623 ± 0.004 | |
| 7.95 ± 0.11 | 0.964 ± 0.004 | NA | NA | NA | NA | NA | NA | NA | NA | 0.575 ± 0.003 | 0.715 ± 0.003 | |
| NA | NA | 7.72 ± 0.19 | 0.942 ± 0.002 | 15.03 ± 0.13 | 0.951 ± 0.007 | 11.22 ± 0.30 | 0.960 ± 0.017 | NA | NA | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | NA | 9.27 ± 0.11 | 0.955 ± 0.003 | NA | NA | |
| NA | NA | NA | NA | NA | NA | NA | NA | 9.42 ± 0.95 | 0.981 ± 0.021 | NA | NA | |
R2 = linear regression factor, NA = not applicable.
Effect of essential oils from C. macrophylla on carrageenan-induced paws edema.
| Group | Treatment | Doses (0.2 mL) | Paw Volume (in mm3) | % Inhibition | |||
|---|---|---|---|---|---|---|---|
| 0 h | 4 h | 24 h | 4 h | 24 h | |||
| I | CMLEO | 5% | 2.34 ± 0.01 | 2.29 ± 0.02b | 2.23 ± 0.02 ab | 2.14 | 4.7 |
| II | CMLEO | 10% | 2.31 ± 0.03 a | 2.21 ± 0.02 ab | 2.12 ± 0.01 ab | 4.33 | 8.23 |
| III | CMLEO | 20% | 2.25 ± 0.02 ab | 2.05 ± 0.02 ab | 1.85 ± 0.03 ab | 8.89 | 17.78 |
| IV | CMEO-II | 5% | 2.29 ± 0.01 a | 2.19 ± 0.02 ab | 2.14 ± 0.03 ab | 4.37 | 6.55 |
| V | CMEO-II | 10% | 2.38 ± 0.02 | 2.30 ± 0.02 b | 2.21 ± 0.02 ab | 3.36 | 7.14 |
| VI | CMEO-II | 20% | 2.41 ± 0.02 | 2.17 ± 0.02 ab | 1.90 ± 0.05 ab | 9.96 | 21.16 |
| VII | CMEO-I | 5% | 2.32 ± 0.03 a | 2.29 ± 0.03 b | 2.21 ± 0.02 ab | 1.29 | 4.74 |
| VIII | CMEO-I | 10% | 2.26 ± 0.02 ab | 2.20 ± 0.02 ab | 2.15 ± 0.03 ab | 2.65 | 4.87 |
| IX | CMEO-I | 20% | 2.27 ± 0.02 a | 2.08 ± 0.03a b | 1.90 ± 0.03 ab | 8.37 | 16.3 |
| X | Control | - | 2.40 ± 0.02 | 2.33 ± 0.01 | 2.32 ± 0.01 | 2.92 | 3.33 |
| XI | Ibuprofen | 40 mg/kg b. wt. | 2.34 ± 0.01 a | 1.73 ± 0.02 a | 1.47 ± 0.02 a | 26.07 | 37.17 |
a = Significant (p < 0.05) as compared to control, b = Significant (p < 0.05) as compared to Ibuprofen. % = Percent reduction in paw volume at different times.
Effect of essential oils from C. macrophylla on formalin-induced mice paw edema.
| Group | Treatment | Dose | Volume of Paw Edema (in mm3) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 Day | 1 Day | 2 Day | 3 Day | 4 Day | 5 Day | 6 Day | 7 Day | 8 Day | 9 Day | 10 Day | |||
| I | CMLEO | 5% (0.2 mL) | 2.28 ± 0.02 | 2.36 ± 0.02 ab | 2.37 ± 0.04 b | 2.42 ± 0.04 b | 2.41 ±0.04 b | 2.40 ± 0.04 b | 2.40 ± 0.04 b | 2.39 ± 0.04 b | 2.39 ± 0.03 b | 2.36 ± 0.03 b | 2.36 ± 0.04 b |
| II | CMLEO | 10% (0.2 mL) | 2.23 ± 0.03 | 2.26 ± 0.02 ab | 2.31 ± 0.03 b | 2.35 ± 0.04 a | 2.34 ±0.03 b | 2.32 ± 0.03 b | 2.32 ± 0.03 b | 2.31 ± 0.03 b | 2.31 ± 0.03 b | 2.31 ± 0.03 b | 2.30 ± 0.03 b |
| III | CMLEO | 20% (0.2 mL) | 2.23 ± 0. 02 | 2.25 ± 0.02 ab | 2.29 ± 0.02 b | 2.30 ± 0.04 a | 2.29 ± 0.04 ab | 2.27 ± 0.03 a | 2.26 ± 0.03 ab | 2.25 ± 0. 02 ab | 2.24 ± 0.02 a | 2.22 ± 0.02 a | 2.22 ± 0.02 b |
| IV | CMEO -II | 5% (0.2 mL) | 2.27 ± 0.03 | 2.30 ± 0.02 ab | 2.36 ± 0.04 b | 2.40 ± 0.05 ab | 2.39 ± 0.05 b | 2.38 ± 0.05 b | 2.38 ± 0.04 b | 2.38 ± 0.03 b | 2.37 ± 0.03 b | 2.36 ± 0.03 b | 2.36 ± 0.03 a |
| V | CMEO-II | 10% (0.2 mL) | 2.24 ± 0.03 | 2.27 ± 0.02 ab | 2.34 ± 0.04 b | 2.38 ± 0.04 ab | 2.37 ± 0.04 b | 2.36 ± 0.03 b | 2.35 ± 0.03 b | 2.33 ± 0.03 b | 2.32 ± 0.02 b | 2.31 ± 0.02 b | 2.30 ± 0.02 b |
| VI | CMEO-II | 20% (0.2 mL) | 2.23 ± 0.02 | 2.24 ± 0.02 ab | 2.26 ± 0.02 a | 2.28 ± 0.03 a | 2.26 ± 0.03 a | 2.25 ± 0.02 a | 2.24 ± 0.02 ab | 2.24 ± 0.02 ab | 2.22 ± 0.03 a | 2.21 ± 0.02 a | 2.20 ± 0.03 a |
| VII | CMEO-I | 5% (0.2 mL) | 2.28 ± 0.02 | 2.29 ± 0.02 ab | 2.37 ± 0.03 b | 2.42 ± 0.04 b | 2.41 ± 0.03 b | 2.41 ± 0.03 b | 2.41 ± 0.03 b | 2.41 ± 0.02 b | 2.41 ± 0.02 b | 2.41 ± 0.02 b | 2.40 ± 0.02 b |
| VIII | CMEO-I | 10% (0.2 mL) | 2.26 ± 0.03 | 2.29 ± 0.02 ab | 2.32 ± 0.03 b | 2.36 ± 0.04 a | 2.35 ± 0.03 b | 2.35 ±0.03 b | 2.34 ± 0.02 b | 2.33 ± 0.03 b | 2.35 ± 0.03 b | 2.33 ± 0.03 b | 2.33 ± 0.03 b |
| IX | CMEO-I | 20% (0.2 mL) | 2.26 ± 0.02 | 2.27 ± 0.02 ab | 2.29 ± 0.03 b | 2.31 ± 0.03 a | 2.30 ± 0.02 ab | 2.29 ± 0.02 ab | 2.27 ± 0.01 ab | 2.27 ± 0.02 ab | 2.25 ± 0.02 ab | 2.24 ± 0.02 a | 2.24 ± 0.02 ab |
| X | Control | (0.2 mL) | 2.13 ± 0.02 | 2.17 ± 0.04 | 2.38 ± 0.03 | 2.52 ± 0.04 | 2.44 ± 0.02 | 2.39 ± 0.01 | 2.38 ± 0.02 | 2.38 ± 0.01 | 2.36 ± 0.01 | 2.36 ± 0.02 | 2.37 ± 0.03 |
| XI | Ibuprofen | 10 mg/kg | 2.11 ± 0.02 | 2.13 ± 0.02 a | 2.19 ±0.01 a | 2.27 ± 0.01 a | 2.21 ± 0.02 a | 2.19 ± 0.01 a | 2.15 ± 0.01 a | 2.16 ± 0.01 a | 2.17 ± 0.01 a | 2.19 ± 0.01 b | 2.15 ± 0.02 a |
a = Significant (p < 0.05) as compared to control, b = Significant (p < 0.05) as compared to Ibuprofen.
Effect of essential oils from C. macophylla on acetic acid induced writhing in mice.
| Group | Treatment | Doses | Writhing Counts | % Writhings | Inhibition (%) |
|---|---|---|---|---|---|
| I | CMLEO | 5% | 115.83 ± 8.06 ab | 83.53 | 16.47 |
| II | CMLEO | 10% | 107.00 ± 4.52 ab | 77.16 | 22.84 |
| III | CMLEO | 20% | 95.00 ± 9.01 ab | 69.95 | 31.49 |
| IV | CMEO -II | 5% | 112.33 ± 5.28 ab | 81 | 18.99 |
| V | CMEO-II | 10% | 104.33 ± 7.09 ab | 75.24 | 24.76 |
| VI | CMEO-II | 20% | 85.33 ± 7.74 a | 61.53 | 38.46 |
| VII | CMEO-I | 5% | 119.67 ± 7.09 ab | 86.3 | 13.7 |
| VIII | CMEO-I | 10% | 111.67 ± 6.12 ab | 80.53 | 19.47 |
| IX | CMEO-I | 20% | 103.00 ± 4.86 ab | 74.28 | 25.72 |
| X | Control | - | 138.67 ± 5.75 | - | - |
| XI | Ibuprofen | 40 mg/kg b. wt. | 77.67 ± 6.86 a | 56.01 | 43.99 |
a = Significant (p < 0.05) as compared to control, b = Significant (p < 0.05) as compared to Ibuprofen.
Effect of essential oils from C. macrophylla on brewer’s yeast-induced pyrexia in mice.
| Group | Treatment | Dose | Body Temperature (°C) | Body Temperature After Administration of Drug (°C) | % Reduction in Body Temperature | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before Injection of Yeast | After 18 h of Yeast Injection | 1 h | 3 h | 24 h | 1 h | 3 h | 24 h | |||
| I | CMLEO | 5% (0.2 mL) | 37.57 ± 0.05 | 38.57 ± 0.04 | 38.29 ± 0.03 b | 38.18 ± 0.04 ab | 38.13 ± 0.03 b | 28 | 39 | 44.00 |
| II | CMLEO | 10% (0.2 mL) | 37.47 ± 0.03 | 38.49 ± 0.03 b | 38.15 ± 0.03 ab | 38.01 ± 0.04 ab | 37.94 ± 0.04 ab | 33.33 | 47.05 | 53.92 |
| III | CMLEO | 20% (0.2 mL) | 37.56 ± 0.02 a | 38.58 ± 0.04 | 37.99 ± 0.03 ab | 37.86 ± 0.04 ab | 37.77 ± 0.05 ab | 57.84 | 70.59 | 79.41 |
| IV | CMEO-II | 5% (0.2 mL) | 37.55 ± 0.03 | 38.56 ± 0.03 | 38.27 ± 0.02 b | 38.12 ± 0.03 ab | 38.08 ± 0.03 ab | 28.71 | 43.56 | 47.52 |
| V | CMEO-II | 10% (0.2 mL) | 37.49 ± 0.04 | 38.51 ± 0.03 | 38.14 ± 0.04 ab | 37.97 ± 0.04 ab | 37.90 ± 0.04 ab | 36.27 | 52.94 | 59.8 |
| VI | CMEO-II | 20% (0.2 mL) | 37.51 ± 0.04 | 38.55 ± 0.03 | 37.89 ± 0.04 ab | 37.73 ± 0.02 ab | 37.63 ± 0.03 a | 63.46 | 78.85 | 88.46 |
| VII | CMEO-I | 5% (0.2 mL) | 37.48 ± 0.03 | 38.46 ± 0.03 b | 38.19 ± 0.03 ab | 38.12 ± 0.04 ab | 38.06 ± 0.04 ab | 27.55 | 34.69 | 40.82 |
| VIII | CMEO-I | 10% (0.2 mL) | 37.52 ± 0.02 | 38.53 ± 0.03 | 38.20 ± 0.04 ab | 38.07 ± 0.04 ab | 38.00 ± 0.05 ab | 32.67 | 45.54 | 52.47 |
| IX | CMEO-I | 20% (0.2 mL) | 37.49 ± 0.02 | 38.54 ± 0.02 | 37.97 ± 0.02 ab | 37.87 ± 0.02 ab | 37.76 ± 0.05 ab | 54.28 | 63.81 | 74.29 |
| X | Control | (0.2 mL) | 37.46 ± 0.02 | 38.50 ± 0.03 | 38.36 ± 0.04 | 38.30 ± 0.03 | 38.22 ± 0.03 | 13.46 | 19.23 | 26.92 |
| XI | Paracetamol | 33.0 mg/kg | 37.50 ± 0.03 | 38.59 ± 0.04 a | 37.75 ± 0.04 a | 37.61 ± 0.03 a | 37.54 ± 0.04 a | 77.06 | 89.91 | 96.33 |
a = Significant (p < 0.05) as compared to control, b = Significant (p < 0.05) as compared to Paracetamol.